Status:
COMPLETED
Effect of Continuing vs. Discontinuing ACE Inhibitors on Renal Function After Coronary Angiography
Lead Sponsor:
Tanta University
Conditions:
Contrast-Induced Nephropathy
Coronary Angiography
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
This clinical trial evaluates whether continuing or withholding ACE inhibitors (specifically Ramipril) before coronary angiography affects the risk of contrast-induced nephropathy (CIN). CIN is a know...
Detailed Description
This randomized controlled study is designed to provide clinical evidence on whether withholding ACE inhibitors prior to contrast administration in coronary angiography affects kidney function. Partic...
Eligibility Criteria
Inclusion
- Adults (≥18 years) scheduled for elective coronary angiography
- Currently on ACE inhibitor (Ramipril)
- Serum creatinine ≤1.5 mg/dL
Exclusion
- STEMI within last 2 weeks
- NYHA Class IV heart failure
- CrCl \<50 mL/min
- Serum potassium \>5.0 mEq/L
- Recent contrast exposure
- Pregnancy or breastfeeding
- Cardiogenic shock or sepsis
- Severe uncontrolled hypertension
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT07184918
Start Date
February 1 2024
End Date
June 1 2025
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy Tanta university
Tanta, Gharbia Governorate, Egypt, 31527